AC
GRI

Armistice Capital’s GRI Bio GRI Stock Holding History

Armistice Capital’s Portfolio GRI Stock Details GRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-105
Closed -$96.4K – 289
2024
Q2 		$96.4K Buy
+105
New +$250K ﹤0.01% 226

Other funds holding GRI

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Armistice Capital's GRI Position: Q3 2024 in Review

Armistice Capital sold out of GRI Bio (GRI) in Q3 2024, closing a stake of 105 shares — an estimated $96.4K sold.

Armistice Capital first reported a position in GRI in Q2 2024 and held it in 1 quarter. The position peaked at $96.4K in Q2 2024. 6 funds tracked by Wall St. Rank hold GRI as of Q3 2024.

  • Armistice Capital reported no remaining GRI Bio position as of Q3 2024 after selling out during the quarter.
  • Armistice Capital sold 105 GRI Bio shares in Q3 2024, an estimated $96.4K.
  • Armistice Capital first reported a position in GRI Bio in Q2 2024 and held it in 1 quarter.
  • Armistice Capital's GRI Bio position peaked at $96.4K in Q2 2024.
  • 6 funds tracked by Wall St. Rank held GRI Bio as of Q3 2024.

Based on Armistice Capital's 13F filing for Q3 2024, filed 14 Nov 2024.